| | Factors | Survivors () | Nonsurvivors () | value | Brut OR (95% CI) |
| | Age, | | | 0.150 | | | , (%) | 27 (26.7%) | 10 (25.6%) | 0.896 | 0.94 (0.40-2.19) | | Female gender, (%) | 67 (66.3%) | 21 (53.8%) | 0.170 | | | Comorbidities, (%) | | Diabetes | 15 (14.85%) | 7 (17.94%) | 0.414 | | | Cancer | 3 (2.97%) | 1 (2.56%) | 0.690 | | | Heart disease | 22 (21.78%) | 11 (28.2%) | 0.277 | | | Stroke | 6 (5.9%) | 2 (5.1%) | 0.853 | 0.85 (0.16-4.43) | | Antithrombotic therapy | 5 (5%) | 10 (25.6%) | ≤0.001 | 6.62 (2.09-20.93) | | History of complicated lithiasic disease | 9 (8.9%) | 2 (5.1%) | 0.456 | 0.55 (0.11-2.68) | | History of biliary procedure | 41 (40.6%) | 14 (35.9%) | 0.610 | 0.82 (0.38-1.76) | | Time to hospital consultation (days), | | 12.03 ± 5.426 | 0.003 | | | Type of admission, (%) | | Emergency | 85 (84.2%) | 27 (69.23%) | 0.048 | 0.42 (0.17-1.00) | | Surgical ward | 15 (14.9%) | 7 (17.9%) | 0.652 | 1.25 (0.46-3.35) | | Medical ward | 1 (1%) | 5 (12.82%) | 0.002 | 14.70 (1.65-130.3) | | Charcot triad, (%) | 94 (96.03%) | 36 (92.3%) | 0.563 | | | Etiology, (%) | | Lithiasic | 75 (74.3%) | 22 (56.4%) | 0.040 | 0.44 (0.20-0.97) | | Tumor | 10 (9.9%) | 11 (28.2%) | 0.007 | | | Hydatic | 12 (11.9%) | 6 (15.4%) | 0.579 | 1.34 (0.46-3.88) | | Severity assessment upon admission | | Septic shock, (%) | 7 (6.9%) | 25 (64.1%) | ≤0.001 | | | Respiratory failure, (%) | 11 (10.89%) | 15 (38.5%) | ≤0.001 | | | GCS, | 14.52 | 13.07 | ≤0.001 | | | GCS< 15, (%) | 22 (21.8%) | 25 (64.21%) | ≤0.001 | 6.41 (2.86-14.37) | | Quick-, (%) | 24 (23.76%) | 27 (69.2%) | ≤0.001 | | | SOFA, | | | ≤0.001 | | | TOKYO Grade III, (%) | 76 (75.2%) | 38 (97.4%) | 0.002 | | | Laboratory finding upon admission, | | Creatinine, mg/l | 23.20 | 37.18 | 0.001 | | | White blood cell count, /mm3 | 19718.4 | 23888.5 | 0.257 | | | C-reactive protein, mg/l | 197.5 | 209.84 | 0.496 | | | Aspartate amino transferase, IU/l | 166.91 | 208.25 | 0.185 | | | Alanine aminotransferase, IU/l | 141.81 | 202.58 | 0.139 | | | Alkaline phosphatase, IU/l | 364.92 | 478 | 0.052 | | | Total bilirubin, mg/l | 106.5 | 174.76 | 0.002 | | | Prothrombin , (%) | 33 (32.7%) | 16 (41.02%) | 0.353 | | | Organ support therapies | | Catecholamines, (%) | 21 (20.8%) | 32 (82.1%) | ≤0.001 | 17.41 (6.74-44.96) | | Mechanical ventilation, (%) | 6 (5.9%) | 26 (66.7%) | ≤0.001 | 31.66 (10.96-91.41) | | Dialysis, (%) | 2 (2%) | 7 (17.9%) | 0.001 | 10.82 (2.14-54.78) | | Initial empiric antibiotherapy, (%) | | Amoxicillin + clavulanic acid | 13 (12.9%) | 4 (10.3%) | 0.671 | 0.77 (2.36-2.53) | | Ceftriaxone + metronidazole | 87 (86.1%) | 35 (89.7%) | 0.568 | 1.40 (0.43-4.57) | | Time to biliary decompression (days), | | | 0.910 | | | Decompression technique, (%) | | Endoscopic | 82 (81.2%) | 29 (74.4%) | 0.371 | 0.67 (0.28-1.61) | | Surgical | 16 (15.8%) | 6 (15.4%) | 0.947 | 0.96 (0.34-2.68) | | Percutaneous | 2 (2%) | 1 (2.6%) | 0.831 | 1.30 (0.11-14.78) | | Persistence of renal failure after decompression, (%) | 3 (3%) | 10 (25.6%) | ≤0.001 | 11.26 (2.90-43.67) | | Persistence of hematological failure after decompression, (%) | 5 (5%) | 35 (89.7%) | ≤0.001 | 168 (42.66-661.50) | | ICU stay (days), | | | 0.988 | | | Septic shock during ICU stay, (%) | 0 (0%) | 35 (89.7%) | ≤0.001 | |
|
|
